Zenas Biopharma Inc. announced results from the Phase 2 MoonStone trial of obexelimab in patients with Relapsing Multiple Sclerosis (RMS). The data were presented in a late-breaking oral session at the ACTRIMS Forum 2026. The study met its primary endpoint, demonstrating a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo over weeks 8 and 12. Obexelimab was reported to be well tolerated, with no new safety signals observed. Additional 24-week data indicated robust and durable activity of obexelimab. The company is also advancing orelabrutinib in global Phase 3 trials for Primary Progressive Multiple Sclerosis and plans to initiate a Phase 3 trial in non-active Secondary Progressive Multiple Sclerosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650956-en) on February 09, 2026, and is solely responsible for the information contained therein.